0001104659-26-048625.txt : 20260424 0001104659-26-048625.hdr.sgml : 20260424 20260424163012 ACCESSION NUMBER: 0001104659-26-048625 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20260422 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20260424 DATE AS OF CHANGE: 20260424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Solana Co CENTRAL INDEX KEY: 0001610853 STANDARD INDUSTRIAL CLASSIFICATION: FINANCE SERVICES [6199] ORGANIZATION NAME: 09 Crypto Assets EIN: 364787690 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38445 FILM NUMBER: 26894746 BUSINESS ADDRESS: STREET 1: 642 NEWTOWN YARDLEY ROAD CITY: NEWTOWN STATE: PA ZIP: 18940 BUSINESS PHONE: 215-944-6100 MAIL ADDRESS: STREET 1: 642 NEWTOWN YARDLEY ROAD CITY: NEWTOWN STATE: PA ZIP: 18940 FORMER COMPANY: FORMER CONFORMED NAME: HELIUS MEDICAL TECHNOLOGIES, INC. DATE OF NAME CHANGE: 20180525 FORMER COMPANY: FORMER CONFORMED NAME: HELIUS MEDICAL TECHNOLOGIES, INC DATE OF NAME CHANGE: 20180517 FORMER COMPANY: FORMER CONFORMED NAME: HELIUS MEDICAL TECHNOLOGIES, INC. DATE OF NAME CHANGE: 20140613 8-K 1 hsdt-20260422x8k.htm 8-K SOLANA COMPANY_April 22, 2026
0001610853false00016108532026-04-222026-04-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 22, 2026

Graphic

SOLANA COMPANY

(Exact name of registrant as specified in its charter)

-

Delaware

001-38445

36-4787690

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

642 Newtown Yardley Road, Suite 100

Newtown, PA

 

18940

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (215) 944-6100

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  ​ ​ ​

Trading

Symbol(s)

  ​ ​ ​

Name of each exchange on which registered

Class A Common Stock, $0.001 par value

HSDT

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

On April 22, 2026 and April 23, 2026, Sherrie Perkins and Paul Buckman, respectively, notified Solana Company (the “Company”) of their decision to not stand for re-election as a director when their current terms expire at the Company’s 2026 Annual Meeting of Stockholders, scheduled to be held on May 21, 2026 (the “Annual Meeting”). Each of Ms. Perkins’s and Mr. Buckman’s decision to not to stand for re-election was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies, practices or strategy, the Company’s management or the Board of Directors of the Company (the “Board”).

(d)

On April 23, 2026, the Board increased the size of the Board from seven to nine members, creating two vacancies on the Board and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed each of Michel Lee and Sergio Mello as directors to fill the newly created vacancies, effective immediately.

Michel Lee, age 56, has been a co-founder and investment partner at Cybertech Partners since October 2018, and co-founder at Hashkey Group Limited (HKEX: 3887.HK) since January 2019. Mr. Lee is a capital market and investment professional with over 25 years of experience in various senior leadership roles in one of the largest global investment banks in Hong Kong, Beijing, Tokyo and London. Mr. Lee has helped various companies to complete strategic transactions including early funding rounds, initial public offerings, structured financings, derivatives, and mergers and acquisitions. Mr. Lee holds a master’s degree in Advanced Information Technology from Imperial College London, and a bachelor’s degree in Physics, Electronics & Computing from University College London.

Sergio Mello, age 44, has served as the global head of stablecoin solutions at Anchorage Digital, where he focuses on the business development and platform offerings for stablecoins, since January 2026 and previously served as its head of stablecoins. Prior to joining Anchorage Digital, Mr. Mello served as the founder and chief executive officer of Lago Finance, a consortium of financial institutions designed to enhance settlements with tokenized cash, from April 2022 to November 2023. Mr. Mello is a serial entrepreneur who has achieved exits in web1, web2, and web3. He has also served an advisor to Nodle, a digital trust network, from October 2017 to May 2022 and as a crypto advisor to Reddit, an online open community platform, from January 2021 to December 2021. Mr. Mello holds a bachelor's degree in Electrical Engineering from Politecnico di Torino.

Mr. Lee and Mr. Mello will receive cash and equity compensation for their respective service on the Board in accordance with the Company’s non-employee director compensation policy described under the section titled “Non-Employee Director Compensation” in the Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission (the “SEC”) on April 10, 2026, which non-employee director compensation policy was filed as Exhibit 10.7 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on May 17, 2021.

In connection with their respective elections, Mr. Lee has entered into and Mr. Mello will enter into the Company’s standard form of indemnification agreement for directors and officers, a copy of which was filed as Exhibit 10.2 to the Company’s Form 8-K, filed with the SEC on September 18, 2025, which requires, among other things, that the Company indemnify each of Mr. Lee and Mr. Mello, under the circumstances and the extent provided for therein, against certain expenses, judgements, fines and other amounts incurred by him as a result of being made party to certain actions, suits, claims and other proceedings, by reason of his status as a director, officer, employee, or agent of the company or any other entity for which he was serving as a director, officer, employee or agent at the request of the Company.

There are no arrangements or understandings between Mr. Lee and Mr. Mello and any other person pursuant to which they were elected as directors. Neither Mr. Lee nor Mr. Mello have any family relationships with any of the Company’s directors or executive officers. Neither Mr. Lee nor Mr. Mello have a direct or indirect material interest in any transaction that would require disclosure under Item 404(a) of Regulation S-K.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SOLANA COMPANY.

Dated: April 24, 2026

By:

/s/ Jeffrey S. Mathiesen

Jeffrey S. Mathiesen

Chief Financial Officer, Treasurer and Secretary

3

GRAPHIC 2 hsdt-20260422x8k001.jpg GRAPHIC begin 644 hsdt-20260422x8k001.jpg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end EX-101.SCH 3 hsdt-20260422.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 hsdt-20260422_lab.xml EX-101.LAB EX-101.PRE 5 hsdt-20260422_pre.xml EX-101.PRE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Document and Entity Information
Apr. 22, 2026
Document and Entity Information [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 22, 2026
Entity Registrant Name SOLANA COMPANY
Entity Central Index Key 0001610853
Entity Emerging Growth Company false
Entity File Number 001-38445
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 36-4787690
Entity Address, Address Line One 642 Newtown Yardley Road
Entity Address, Adress Line Two Suite 100
Entity Address, City or Town Newtown
Entity Address State Or Province PA
Entity Address, Postal Zip Code 18940
City Area Code 215
Local Phone Number 944-6100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, $0.001 par value
Trading Symbol HSDT
Security Exchange Name NASDAQ
XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.26.1 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports hsdt-20260422.xsd hsdt-20260422_lab.xml hsdt-20260422_pre.xml hsdt-20260422x8k.htm hsdt-20260422x8k001.jpg http://xbrl.sec.gov/dei/2024 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hsdt-20260422x8k.htm": { "nsprefix": "hsdt", "nsuri": "http://www.heliusmedical.com/20260422", "dts": { "schema": { "local": [ "hsdt-20260422.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "labelLink": { "local": [ "hsdt-20260422_lab.xml" ] }, "presentationLink": { "local": [ "hsdt-20260422_pre.xml" ] }, "inline": { "local": [ "hsdt-20260422x8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_4_22_2026_To_4_22_2026_4deARLS8kkOjTditmKXAOQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hsdt-20260422x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_22_2026_To_4_22_2026_4deARLS8kkOjTditmKXAOQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hsdt-20260422x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Adress Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001104659-26-048625-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-26-048625-xbrl.zip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false 8-K 2026-04-22 SOLANA COMPANY DE 001-38445 36-4787690 642 Newtown Yardley Road Suite 100 Newtown PA 18940 215 944-6100 false false false false Class A Common Stock, $0.001 par value HSDT NASDAQ false